interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Dihydroergotamine Mesylate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Dihydroergotamine Mesylate, and who makes it?

Dihydroergotamine Mesylate appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 7 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 22.2 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Dihydroergotamine Mesylate4 dosage-form groups in the Orange Book
7generic makers listed
  1. Dihydroergotamine Mesylate appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 7 generic makers listed as marketed across them.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 22.2 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Injectable, Injection

Four or more generic makers listed

Every brand product here is listed as discontinued. 4 generic makers with 5 generic products listed as marketed; the first generic approval is dated 28 April 2003.

200020052010201520202025203004Hikma Pharmaceuticals Usa Inc, first approval 9 June 2003Sagent Pharmaceuticals Inc, first approval 11 July 2018Milla Pharmaceuticals Inc, first approval 7 January 2020Gland Pharma Ltd, first approval 18 August 2023data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Hikma Pharmaceuticals Usa Inc9 June 20032
Sagent Pharmaceuticals Inc11 July 20181
Milla Pharmaceuticals Inc7 January 20201
Gland Pharma Ltd18 August 20231

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Spray, Metered, Nasal

Four or more generic makers listed

Brand listed as marketed: Migranal and Trudhesa. 4 generic makers with 4 generic products listed as marketed; the first generic approval is dated 28 February 2020.

199520002005201020152020202520302035204004brand 1997Hikma Pharmaceuticals Usa Inc, first approval 28 February 2020Cipla Ltd, first approval 20 May 2020Rubicon Research Ltd, first approval 22 June 2023Somerset Therapeutics Llc, first approval 26 February 2025data datePatent 9550036 listed to expire 5 September 2032Patent 10507295 listed to expire 25 December 2032Patent 10940278 listed to expire 23 January 2033Patent 9919117 listed to expire 17 March 2033Patent 11266799 listed to expire 5 November 2036Patent 11185497 listed to expire 4 January 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Hikma Pharmaceuticals Usa Inc28 February 20201
Cipla Ltd20 May 20201
Rubicon Research Ltd22 June 20231
Somerset Therapeutics Llc26 February 20251

Patents and exclusivities still listed

  • 5 September 2032Patent 9550036 drug product
  • 25 December 2032Patent 10507295 drug product
  • 23 January 2033Patent 10940278 drug product
  • 17 March 2033Patent 9919117 drug product
  • 5 November 2036Patent 11266799 drug product
  • 4 January 2039Patent 11185497

Powder, Nasal

Brand listed, no generic listed as marketed

Brand listed as marketed: Atzumi. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 12594273 listed to expire 24 September 2033Patent 11872314 listed to expire 4 August 2037Patent 10792253 listed to expire 4 August 2037Patent 10758532 listed to expire 11 December 2039Patent 12263162 listed to expire 11 December 2039Patent 12102754 listed to expire 12 October 2041Patent 11744967 listed to expire 12 October 2041Exclusivity NP to 30 April 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 30 April 2028Exclusivity NP Atzumi
  • 24 September 2033Patent 12594273 drug product
  • 4 August 2037Patent 11872314 drug product
  • 4 August 2037Patent 10792253 drug product
  • 11 December 2039Patent 10758532 drug product
  • 11 December 2039Patent 12263162 drug product
  • 12 October 2041Patent 12102754 drug product
  • 12 October 2041Patent 11744967 drug product

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Brekiya (Autoinjector). No generic is listed as marketed.

2020202520302035204001brand 2025data datePatent 11819501 listed to expire 26 February 2039Patent 10532049 listed to expire 26 February 2039Patent 12533351 listed to expire 26 February 2039Patent 11304942 listed to expire 26 February 2039Patent 11541043 listed to expire 20 March 2039Patent 12329749 listed to expire 27 May 2039Patent 11083712 listed to expire 30 June 2039Patent 12414941 listed to expire 24 August 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 26 February 2039Patent 11819501
  • 26 February 2039Patent 10532049 drug product
  • 26 February 2039Patent 12533351 drug product
  • 26 February 2039Patent 11304942 drug product
  • 20 March 2039Patent 11541043 drug product
  • 27 May 2039Patent 12329749 drug product
  • 30 June 2039Patent 11083712 drug product
  • 24 August 2039Patent 12414941 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.